Guerbet: A Century of Contrast Media and Future Medical Imaging Innovations
Founded in 1926, French company Guerbet has nearly a century of history in developing contrast agents for medical imaging. It is now expanding into AI and radiotherapeutics.
Guerbet, a French company established in 1926, has built a significant legacy in the field of medical imaging. The company specializes in the development and manufacturing of contrast agents used in diagnostic procedures such as X-ray and MRI.
The company's origins trace back to 1901, when Marcel Guerbet developed the world's first iodinated contrast medium. Today, Guerbet employs over 2,900 people globally. A pivotal moment in its expansion occurred in 2015 with the acquisition of Mallinckrodt's "Contrast Media and Injection Systems" business, elevating Guerbet to the top three global players in medical imaging solutions.
Looking ahead, Guerbet is investing in emerging technologies. In 2023, the company began investing in INTRASENSE to develop AI-driven diagnostic support tools for radiologists. In May 2024, Guerbet entered a strategic partnership with Nuclidium to advance radiotherapeutics, particularly focusing on copper isotopes for cancer treatment.
Guerbet's flagship product, Lipiodol, an iodinated oil, has been a staple in medical imaging for over a century. The company is exploring new research avenues, including "Vectorized Internal Radiotherapy" (VIR) and the identification of proteomic biomarkers. Guerbet is also developing novel therapeutic approaches, such as the LIPIOJOINT trial targeting knee osteoarthritis.
Recent product launches include the Elucirem™ contrast agent in the US and European markets. Guerbet's long-standing history, coupled with its ongoing investments in innovation, demonstrates a commitment to advancing medical imaging and therapeutic interventions.